Works matching DE "GEFITINIB"
Results: 808
Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 3, p. 381, doi. 10.1007/s00228-020-03013-9
- By:
- Publication type:
- Article
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 10, p. 1427, doi. 10.1007/s00228-020-02926-9
- By:
- Publication type:
- Article
Clinical trials: More trials, fewer tribulations.
- Published in:
- Nature, 2014, v. 509, n. 7502, p. S55, doi. 10.1038/509S55a
- By:
- Publication type:
- Article
Effect of Crosslinking Agents on Chitosan Hydrogel Carriers for Drug Loading and Release for Targeted Drug Delivery.
- Published in:
- Gels (2310-2861), 2024, v. 10, n. 7, p. 421, doi. 10.3390/gels10070421
- By:
- Publication type:
- Article
Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.
- Published in:
- Communications Biology, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42003-024-07339-3
- By:
- Publication type:
- Article
Curcuminoids combined with gefitinib mediated apoptosis and autophagy of human oral cancer SAS cells in vitro and reduced tumor of SAS cell xenograft mice in vivo.
- Published in:
- Environmental Toxicology, 2018, v. 33, n. 8, p. 821, doi. 10.1002/tox.22568
- By:
- Publication type:
- Article
Preparation and evaluation of biological activity of ZSM-5 nanoparticles loaded with gefitinib for the treatment of non-small cell lung carcinoma.
- Published in:
- Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e112449
- By:
- Publication type:
- Article
MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2019, v. 23, n. 6, p. 2444
- By:
- Publication type:
- Article
B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns.
- Published in:
- BioMed Research International, 2020, p. 1, doi. 10.1155/2020/8824805
- By:
- Publication type:
- Article
Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs.
- Published in:
- Clinical & Translational Medicine, 2018, v. 7, n. 1, p. 1, doi. 10.1186/s40169-018-0185-6
- By:
- Publication type:
- Article
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2015, v. 40, n. 6, p. 661, doi. 10.1111/jcpt.12332
- By:
- Publication type:
- Article
DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF GEFITINIB IN BULK AND ITS PHARMACEUTICAL FORMULATIONS.
- Published in:
- International Journal of Pharmaceutical, Chemical & Biological Sciences, 2013, v. 3, n. 4, p. 1305
- By:
- Publication type:
- Article
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 109, doi. 10.2147/LCTT.S119644
- By:
- Publication type:
- Article
Gefitinib frequently induces liver damagein patients with lung adenocarcinoma previously treated by chemotherapy.
- Published in:
- Lung Cancer: Targets & Therapy, 2013, v. 4, p. 9, doi. 10.2147/LCTT.S45172
- By:
- Publication type:
- Article
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2012, v. 3, p. 91, doi. 10.2147/LCTT.S12959
- By:
- Publication type:
- Article
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
- Published in:
- Human & Experimental Toxicology, 2016, v. 35, n. 5, p. 526, doi. 10.1177/0960327115595686
- By:
- Publication type:
- Article
Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int. J. Cancer, 115: 630–640. https://doi.org/10.1002/ijc.20917
- Published in:
- 2019
- Publication type:
- Correction Notice
A landscape of response to drug combinations in non-small cell lung cancer.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39528-9
- By:
- Publication type:
- Article
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.
- Published in:
- Genes, 2023, v. 14, n. 10, p. 1906, doi. 10.3390/genes14101906
- By:
- Publication type:
- Article
Ramucirumab-induced Multiple Haemangiomas of the Skin: Two Case Reports.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy.
- Published in:
- International Journal of Women's Health, 2015, v. 7, p. 673, doi. 10.2147/IJWH.S55556
- By:
- Publication type:
- Article
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
- Published in:
- Science Signaling, 2015, v. 8, n. 379, p. 1, doi. 10.1126/scisignal.aaa0725
- By:
- Publication type:
- Article
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2015, v. 34, p. 1, doi. 10.1186/s13046-015-0251-5
- By:
- Publication type:
- Article
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2014, v. 33, n. 1, p. 1, doi. 10.1186/1756-9966-33-52
- By:
- Publication type:
- Article
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS‐dependent apoptosis and ferroptosis.
- Published in:
- Kaohsiung Journal of Medical Sciences, 2023, v. 39, n. 7, p. 699, doi. 10.1002/kjm2.12684
- By:
- Publication type:
- Article
Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
- Published in:
- Neoplasma, 2022, v. 69, n. 3, p. 648, doi. 10.4149/neo_2022_211103N1568
- By:
- Publication type:
- Article
Non-small cell lung cancer - genetic predictors.
- Published in:
- Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2013, v. 157, n. 2, p. 125, doi. 10.5507/bp.2013.034
- By:
- Publication type:
- Article
Pyogenic Granuloma in a Patient on Gefitinib.
- Published in:
- Acta Médica Portuguesa, 2016, v. 29, n. 6, p. 416, doi. 10.20344/amp.6343
- By:
- Publication type:
- Article
Effectiveness of pharmacist-managed oncology ambulatory care for patients with non-small cell lung cancer in Taiwan.
- Published in:
- Journal of Food & Drug Analysis, 2024, v. 32, n. 4, p. 558, doi. 10.38212/2224-6614.3528
- By:
- Publication type:
- Article
ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 4, p. 2382, doi. 10.3390/ijms25042382
- By:
- Publication type:
- Article
Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 3, p. 1374, doi. 10.3390/ijms25031374
- By:
- Publication type:
- Article
6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 2639, doi. 10.3390/ijms24032639
- By:
- Publication type:
- Article
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 14, p. 8025, doi. 10.3390/ijms23148025
- By:
- Publication type:
- Article
The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer.
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
Individual and Combined Treatments with Methylated Resveratrol Analogue DMU-214 and Gefitinib Inhibit Tongue Cancer Cells Growth via Apoptosis Induction and EGFR Inhibition.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 12, p. 6180, doi. 10.3390/ijms22126180
- By:
- Publication type:
- Article
KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 10, p. 5384, doi. 10.3390/ijms22105384
- By:
- Publication type:
- Article
Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 1, p. 240, doi. 10.3390/ijms22010240
- By:
- Publication type:
- Article
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 6, p. 1431, doi. 10.3390/ijms20061431
- By:
- Publication type:
- Article
Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 6, p. 1731, doi. 10.3390/ijms19061731
- By:
- Publication type:
- Article
Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 12, p. 1998, doi. 10.3390/ijms17121998
- By:
- Publication type:
- Article
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 10, p. 1618, doi. 10.3390/ijms17101618
- By:
- Publication type:
- Article
CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10735-3
- By:
- Publication type:
- Article
ADAURA, a Bridge Connecting Disease Control with Long-term Survival.
- Published in:
- Science Progress, 2021, p. 1, doi. 10.1177/00368504211050289
- By:
- Publication type:
- Article
The economic evaluation of personalised oncology medicines: ethical challenges.
- Published in:
- Medical Journal of Australia, 2013, v. 199, n. 7, p. 471, doi. 10.5694/mja13.10046
- By:
- Publication type:
- Article
Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall cell lung cancer: A meta analysis from randomized controlled clinical trials.
- Published in:
- Indian Journal of Cancer, 2014, v. 51, p. e86, doi. 10.4103/0019-509X.154070
- By:
- Publication type:
- Article
Ignore molecular oncology at your peril.
- Published in:
- Indian Journal of Cancer, 2014, v. 51, n. 2, p. 150, doi. 10.4103/0019-509X.138258
- By:
- Publication type:
- Article
Chemoresistance Mechanisms in Non-Small Cell Lung Cancer—Opportunities for Drug Repurposing.
- Published in:
- Applied Biochemistry & Biotechnology, 2024, v. 196, n. 7, p. 4382, doi. 10.1007/s12010-023-04595-7
- By:
- Publication type:
- Article
Folate-conjugated zein/Fe<sub>3</sub>O<sub>4</sub> nanocomplexes for the enhancement of cellular uptake and cytotoxicity of gefitinib.
- Published in:
- Journal of Materials Science, 2018, v. 53, n. 21, p. 14907, doi. 10.1007/s10853-018-2684-7
- By:
- Publication type:
- Article